Seneca Biopharma's Merger Partner Leading BioSciences' Lead Asset Shows Efficacy In Lower Post-Surgical Adhesions

Privately-held Leading BioSciences Inc entered into a definitive agreement for a reverse merger with Seneca Biopharma Inc SNCA has announced data from an open-label gastrointestinal (GI) surgery study with lead asset LB1148.
Data provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection.
No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148.
Previously the company described statistically significant data from the Phase 1, single-site, open-label, investigator-sponsored trial.
LB1148 treated patients had a statistically significant reduction in hospital length of stay by 1.3-days compared to the expected length of stay.
Generally, treatment with LB1148 was well tolerated. AEs were not considered unexpected in this patient population. None of the AEs or SAEs reported were considered drug-related by the sponsor-investigator.
Price Action: SNCA shares are up 3.2% at $1.6 in premarket on the last check Tuesday.